A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

This is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups, afterwards some subjects entered the immune persistence group.

NCT Number	NCT06700148
Lead Sponsor	CanSino Biologics Inc.
Conditions	Meningococcal Meningitis
Enrollment	840 participants
Start Date	2024-12-14
Primary Completion	2025-02-19 (estimated)
Study Completion	2025-07-16 (estimated)
Updated on ClinicalTrials.gov	2026-08-06